FidoCure

FidoCure is a precision medicine platform developed by One Health Company that offers personalized cancer treatment for dogs. It employs genomic-guided DNA testing to identify genetic mutations driving cancer in dogs and matches these mutations to individualized treatment plans using targeted therapies. Launched in 2022, FidoCure's proprietary canine cancer dataset comprises genomic information from over 4,000 diagnosed dogs, enabling it to identify the most effective treatments based on a dog's specific genetic profile.

FidoCure's technology streamlines access to cutting-edge cancer diagnostics and treatments for pet owners. Over 40 veterinarians within Thrive Pet healthcare's network have utilized FidoCure's platform in over 200 canine cancer cases, with approximately 63% of the dogs showing positive healing responses as of July 2023. Through partnerships with companies like Ardent Animal Health and IDEXX Laboratories, FidoCure aims to expand its reach and provide advanced cancer care options to more veterinary clinics nationwide.

Key customers and partnerships

In July 2023, FidoCure announced a partnership with Ardent Animal Health, a global leader in advanced treatments for pets. This collaboration combines efforts to increase access to Ardent's cancer treatment pipeline and FidoCure's genomic testing platform, fostering innovation in the pet oncology market.

IDEXX Laboratories, a global leader in pet healthcare innovation, announced in January 2022 that it would offer FidoCure's Next Generation DNA Sequencing Test to its veterinary customers across the US and Canada. This partnership enables FidoCure to significantly expand its proprietary canine cancer database and make new discoveries benefiting dogs and humans with cancer.